"Infliximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chimeric monoclonal antibody to TNF ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE.
| Descriptor ID |
D000069285
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.608 D12.776.124.790.651.114.224.537 D12.776.377.715.548.114.224.642
|
| Concept/Terms |
Infliximab- Infliximab
- MAb cA2
- Monoclonal Antibody cA2
- cA2, Monoclonal Antibody
|
Below are MeSH descriptors whose meaning is more general than "Infliximab".
Below are MeSH descriptors whose meaning is more specific than "Infliximab".
This graph shows the total number of publications written about "Infliximab" by people in this website by year, and whether "Infliximab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 4 | 4 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Infliximab" by people in Profiles.
-
Valikodath NG, Rathinavelu J, Deaner JD, Buckley M, Grewal DS. Comparison of Reference and Biosimilar Medications for Pediatric Noninfectious Uveitis. Int Ophthalmol Clin. 2024 Oct 01; 64(4):69-73.
-
Godoy-Brewer G, Salem G, Limketkai B, Selaru FM, Grossen A, Policarpo T, Haq Z, Parian AM. Use of Biologics for the Treatment of Inflammatory Conditions of the Pouch: A Systematic Review. J Clin Gastroenterol. 2024 02 01; 58(2):183-194.
-
Deaner JD, Srivastava SK, Hajj-Ali RA, Lowder CY, Venkat AG, Baynes K, Sharma S. Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis. Am J Ophthalmol. 2021 05; 225:172-177.
-
Sharma A, Hafeez Faridi M, Kumar N, Parachuri N, Sharma R, Kuppermann BD, Bandello F, Loewenstein A, Regillo CD. Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. Eye (Lond). 2020 06; 34(6):1008-1009.
-
Karadag AS, Parish LC. Sarcoidosis: A great imitator. Clin Dermatol. 2019 May - Jun; 37(3):240-254.
-
Starr MR, Smith WM. Histoplasmosis Following Systemic Immunomodulatory Therapy for Ocular Inflammation. Am J Ophthalmol. 2019 02; 198:88-96.
-
Yonekawa Y, Thanos A, Faia LJ. Ultra-Widefield Imaging in Granulomatosis With Polyangiitis. JAMA Ophthalmol. 2016 07 14; 134(7):e160034.
-
Groleau PF, Grossberg AL, Gaspari AA. Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated With infliximab. Cutis. 2015 Jun; 95(6):337-42.
-
Bojke L, Epstein D, Craig D, Rodgers M, Woolacott N, Yang H, Sculpher M. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology (Oxford). 2011 Sep; 50 Suppl 4:iv39-iv47.
-
Check JH, Katsoff B, Cohen R. Case report showing that a woman with ulcerative colitis refractory to standard therapy responded well to the sympathomimetic amine dextroamphetamine sulfate. Inflamm Bowel Dis. 2011 Mar; 17(3):870-1.